article thumbnail

STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds

STAT

Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies, and the findings raise questions about the extent to which industry influence may have led to patient harm, according to a new study.

article thumbnail

Janssen rebrands its identity

European Pharmaceutical Review

The Janssen Pharmaceutical Companies of Johnson & Johnson has changed its name to Johnson & Johnson Innovative Medicine (J&J Innovative Medicine). Branding innovation in the pharmaceutical industry This week, Novartis has also finalised changes to its divisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Is prescribing anticancer drugs by body surface area still relevant?

Hospital Pharmacy Europe

The approach was adopted widely, particularly for cytotoxic chemotherapy agents, with the aim of standardising drug exposure and minimising toxicity. 5,6 Freireich et als work further validated this approach, showing that BSA correlated with drug efficacy and toxicity across several chemotherapy agents. 6 Gurney H.

article thumbnail

NICE recommends innovative breast cancer drug

European Pharmaceutical Review

An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable, and endocrine therapy in patients with hormone receptor (HR)-positive breast cancer, if suitable.

article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

article thumbnail

STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more

STAT

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies before the panel with ambitious demands related to their pricing. Bernie Sanders is figuring out just how far bullying drugmakers can take him , STAT writes. Sanders (I-Vt.) AstraZeneca is investing $1.5

article thumbnail

NICE backs two new breast cancer drugs for NHS use

pharmaphorum

. “We’ll continue to demand more for people affected by breast cancer, working with the Government, NHS England, NICE and pharmaceutical companies to ensure new, clinically effective treatments reach patients as quickly as possible, at a fair price for the NHS,” she added.